Mesoblast Limited
Mesoblast Limited
Your view on MSB.AX
Overview
What the company does, where it operates, and who runs it.
About Mesoblast Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Silviu Itescu
- Headquarters
- 55 Collins Street, Melbourne, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Silviu Itescu
- Headquarters
- 55 Collins Street, Melbourne, VIC, AU
Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland.
Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells.
A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease.
Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease.
The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction.
Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China.
It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Mesoblast Limited. Starting points for Mesoblast Limited: EPS -AUD 0.04, beta 0.81 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Mesoblast Limited. Mesoblast Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Mesoblast Limited. Trailing twelve-month EPS for Mesoblast Limited stands at -AUD 0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Hold
Analyst ratings
9 ratings- Strong Buy0
- Buy3
- Hold4
- Sell2
- Strong Sell0
Earnings per share estimates
| Per share | This quarterSep 2026 | Next quarterDec 2026 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | −$0.01 | −$0.02 | −$0.02 | $0.02 |
| Lowest estimate | −$0.01 | −$0.02 | −$0.03 | −$0.06 |
| Highest estimate | −$0.01 | −$0.02 | −$0.01 | $0.16 |
| Number of analysts | 1 | 1 | 3 | 3 |
| A year ago | — | — | −$0.051 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterSep 2026 | Next quarterDec 2026 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | $26.60M | $16.37M | $197.55M | $356.40M |
| Lowest estimate | $26.60M | $16.37M | $175.10M | $266.32M |
| Highest estimate | $26.60M | $16.37M | $221.78M | $429.55M |
| Number of analysts | 1 | 1 | 6 | 6 |
| A year ago | — | — | $122.89M | — |
| Growth vs a year ago | — | — | +60.8% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Mesoblast Limited. Mesoblast Limited has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| CMB.AXCambium Bio Limited | Healthcare | Biotechnology | — | ||
| CYP.AXCynata Therapeutics Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PHGUFPharming Group N.V. | Healthcare | OTC | $1.1B | ||
| PHIOPhio Pharmaceuticals Corp. | Healthcare | NASDAQ | $7.8M | ||
| PHMMFPharma Mar, S.A. | Healthcare | OTC | $1.5B | ||
| PHRM.CNPharmaTher Holdings Ltd. | Healthcare | CNQ | $9.1M | ||
| PHRRFPharmaTher Holdings Ltd. | Healthcare | OTC | $5.3M | ||
| PHVSPharvaris N.V. | Healthcare | NASDAQ | $2.2B | ||
| PHYOFIXICO plc | Healthcare | OTC | $6.5M | ||
| PKTXProtoKinetix, Incorporated | Healthcare | OTC | $2.7M | ||
| PLRXPliant Therapeutics, Inc. | Healthcare | NASDAQ | $36.9M | ||
| PLRZPolyrizon Ltd. | Healthcare | NASDAQ | $10.4M | ||
| PLURPluri Inc. | Healthcare | NASDAQ | $10.1M | ||
| PLXProtalix BioTherapeutics, Inc. | Healthcare | AMEX | $244.5M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXUSVanguard Total International Stock ETF | $163.2B in assets | 0.00% | |
| VEAVanguard FTSE Developed Markets ETF | $231.6B in assets | 0.00% | |
| IEFAiShares Core MSCI EAFE ETF | $188.8B in assets | 0.00% | |
| VSSVanguard FTSE All-World ex-US Small-Cap ETF | $11.6B in assets | 0.03% | |
| DFISDimensional - International Small Cap ETF | $5.8B in assets | 0.03% | |
| IPACiShares Core MSCI Pacific ETF | $2.6B in assets | 0.01% | |
| VPLVanguard FTSE Pacific ETF | $9.0B in assets | 0.01% | |
| DFICDimensional - International Core Equity 2 ETF | $15.4B in assets | 0.01% | |
Largest holders first, then the funds most concentrated in MSB.AX.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Mesoblast Limited. Coverage tracks Mesoblast Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Mesoblast Limited.